Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Ultragenyx Pharmaceutical stock

RARE
US90400D1081
A1XCY0

Price

55.55
Today +/-
-0.87
Today %
-1.71 %
P

Ultragenyx Pharmaceutical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ultragenyx Pharmaceutical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ultragenyx Pharmaceutical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ultragenyx Pharmaceutical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ultragenyx Pharmaceutical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ultragenyx Pharmaceutical Stock Price History

DateUltragenyx Pharmaceutical Price
10/2/202455.55 undefined
10/1/202456.51 undefined
9/30/202455.55 undefined
9/27/202454.43 undefined
9/26/202455.22 undefined
9/25/202456.76 undefined
9/24/202457.48 undefined
9/23/202457.56 undefined
9/20/202458.75 undefined
9/19/202458.78 undefined
9/18/202457.70 undefined
9/17/202458.49 undefined
9/16/202459.36 undefined
9/13/202458.74 undefined
9/12/202457.83 undefined
9/11/202456.33 undefined
9/10/202455.72 undefined
9/9/202455.80 undefined
9/6/202455.24 undefined
9/5/202456.45 undefined
9/4/202456.12 undefined

Ultragenyx Pharmaceutical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ultragenyx Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ultragenyx Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ultragenyx Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ultragenyx Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ultragenyx Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ultragenyx Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ultragenyx Pharmaceutical’s growth potential.

Ultragenyx Pharmaceutical Revenue, EBIT and net profit per share

DateUltragenyx Pharmaceutical RevenueUltragenyx Pharmaceutical EBITUltragenyx Pharmaceutical Net Income
2029e2.88 B undefined0 undefined732.18 M undefined
2028e2.17 B undefined614.65 M undefined280.16 M undefined
2027e1.4 B undefined88.2 M undefined-141.58 M undefined
2026e895.09 M undefined-286.95 M undefined-289.89 M undefined
2025e649.98 M undefined-476.92 M undefined-484.02 M undefined
2024e547.23 M undefined-552.5 M undefined-591.17 M undefined
2023434.25 M undefined-569.21 M undefined-606.64 M undefined
2022363.3 M undefined-648.9 M undefined-707.4 M undefined
2021351.4 M undefined-381.7 M undefined-454 M undefined
2020271 M undefined-330.1 M undefined-186.6 M undefined
2019103.7 M undefined-424.2 M undefined-402.7 M undefined
201851.5 M undefined-371.4 M undefined-197.6 M undefined
20172.6 M undefined-328.9 M undefined-302.1 M undefined
2016100,000 undefined-248 M undefined-245.9 M undefined
20150 undefined-147.7 M undefined-145.6 M undefined
20140 undefined-56.8 M undefined-64.6 M undefined
20130 undefined-32.3 M undefined-50.3 M undefined
20120 undefined-16 M undefined-19.6 M undefined
20110 undefined-6.6 M undefined-7.5 M undefined

Ultragenyx Pharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000.050.10.270.350.360.430.550.650.91.42.172.88
-------2,450.00101.96163.1129.523.4219.5626.0418.6537.9056.7654.3832.96
------100.0098.0491.2697.4295.4492.2989.63------
00000025094264335335389000000
-6-16-32-56-147-248-328-371-424-330-381-648-569-552-476-286886140
-------16,400.00-727.45-411.65-121.77-108.55-178.51-131.11-100.91-73.34-31.966.2728.35-
-7-19-50-64-145-245-302-197-402-186-454-707-606-591-484-289-141280732
-171.43163.1628.00126.5668.9723.27-34.77104.06-53.73144.0955.73-14.29-2.48-18.10-40.29-51.21-298.58161.43
29.129.129.128.836.839.642.549.856.660.867.869.973.54000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Ultragenyx Pharmaceutical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ultragenyx Pharmaceutical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
2011201220132014201520162017201820192020202120222023
                         
0.010.090.050.190.440.380.230.460.761.20.740.750.58
0.1000005.212.732.823.128.440.473.39
0000000000000
0000000.87.111.51316.226.833.97
0.20.31.85.913.321.529.242.951.457.671.76947.62
0.010.090.060.190.450.40.270.520.851.30.860.880.73
0.81.41.337.417.121.82074.7114176.2285.7314.47
000099.311810032.9165.9293.9154.5199.9
0000000000000
000000141.5129.2129131.1130.8160.1166.27
00000044.444.444.444.444.444.444.41
0.40.53.11.52.73.93.43.53.58.820.616.833.79
1.21.94.44.5109.4139221.1197.1284.5464.2665.9661.5758.83
0.010.090.060.20.560.540.490.721.141.761.521.551.49
                         
18.6111.4124.900000.10.10.10.10.10.08
0000.320.8211.221.642.092.7733.143.66
-8.2-27.1-74.8-139-284.7-530.5-832.7-1,030.3-1,433-1,619.6-2,073.6-2,781-3,387.66
000-0.2-0.91.3-5.3-0.3-0.30.4-0.1-0.8-0.17
00000-0.4-0.4-0.30.20.3-1.3-5.71.25
0.010.080.050.180.530.470.380.610.651.150.920.350.28
0.31.21.44.92.95.48.912.312.912.917.143.342.11
0.71.94.47.624.854.661.462.590.4117156.1216.3209.08
00.10.10.10.20.30.70059.27.61.529.24
0000000000000
0000000005006002000
13.25.912.627.960.37174.8103.3189.6181.4261.3280.44
00000000070040000
00000031.231.233.333.333.331.730.06
0.50.83.60.50.66.45.14.8345.1381.6384.8900.1905.1
0.50.83.60.50.66.436.336378.4415.6418.5931.8935.16
000.010.010.030.070.110.110.480.610.61.191.22
0.010.090.060.20.560.540.490.721.141.761.521.551.49
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ultragenyx Pharmaceutical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ultragenyx Pharmaceutical's financial health and stability.

Assets

Ultragenyx Pharmaceutical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ultragenyx Pharmaceutical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ultragenyx Pharmaceutical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ultragenyx Pharmaceutical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-6-16-35-59-145-245-302-197-402-186-454-707-606
000013519812131826
000000-160200-1-1
02-12726-3-24-18104-6361-13
0251755103130-714623270378256
0000000000000
0000000000000
-5-12-31-44-105-160-253-290-345-132-338-380-474
0-10-2-4-10-2-4-24-43-73-146-46
0-1-47-123-2929155-33-13-179-195-291168
00-47-121-28710158-2911-135-122-145214
0000000000000
200000-4000000
148901894678714133636560011910388
17890184467138136336679600118501388
000005100314004900
000-4000000000
1075-78166968-6112320290-416-17181
-6.38-13.59-31.61-46.78-110.94-171.17-256.63-294.65-370.21-176.13-411.79-526.59-521.57
0000000000000

Ultragenyx Pharmaceutical stock margins

The Ultragenyx Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ultragenyx Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ultragenyx Pharmaceutical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ultragenyx Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the Ultragenyx Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ultragenyx Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ultragenyx Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ultragenyx Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ultragenyx Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ultragenyx Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ultragenyx Pharmaceutical Margin History

Ultragenyx Pharmaceutical Gross marginUltragenyx Pharmaceutical Profit marginUltragenyx Pharmaceutical EBIT marginUltragenyx Pharmaceutical Profit margin
2029e89.59 %0 %25.42 %
2028e89.59 %28.38 %12.93 %
2027e89.59 %6.29 %-10.09 %
2026e89.59 %-32.06 %-32.39 %
2025e89.59 %-73.37 %-74.47 %
2024e89.59 %-100.96 %-108.03 %
202389.59 %-131.08 %-139.7 %
202292.21 %-178.61 %-194.72 %
202195.45 %-108.62 %-129.2 %
202097.75 %-121.81 %-68.86 %
201991.32 %-409.06 %-388.33 %
201897.67 %-721.17 %-383.69 %
2017100 %-12,650 %-11,619.23 %
201689.59 %-248,000 %-245,900 %
201589.59 %0 %0 %
201489.59 %0 %0 %
201389.59 %0 %0 %
201289.59 %0 %0 %
201189.59 %0 %0 %

Ultragenyx Pharmaceutical Stock Sales Revenue, EBIT, Earnings per Share

The Ultragenyx Pharmaceutical earnings per share therefore indicates how much revenue Ultragenyx Pharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ultragenyx Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ultragenyx Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ultragenyx Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ultragenyx Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ultragenyx Pharmaceutical Revenue, EBIT and net profit per share

DateUltragenyx Pharmaceutical Sales per ShareUltragenyx Pharmaceutical EBIT per shareUltragenyx Pharmaceutical Earnings per Share
2029e31.25 undefined0 undefined7.94 undefined
2028e23.5 undefined0 undefined3.04 undefined
2027e15.22 undefined0 undefined-1.54 undefined
2026e9.71 undefined0 undefined-3.15 undefined
2025e7.05 undefined0 undefined-5.25 undefined
2024e5.94 undefined0 undefined-6.41 undefined
20235.9 undefined-7.74 undefined-8.25 undefined
20225.2 undefined-9.28 undefined-10.12 undefined
20215.18 undefined-5.63 undefined-6.7 undefined
20204.46 undefined-5.43 undefined-3.07 undefined
20191.83 undefined-7.49 undefined-7.11 undefined
20181.03 undefined-7.46 undefined-3.97 undefined
20170.06 undefined-7.74 undefined-7.11 undefined
20160 undefined-6.26 undefined-6.21 undefined
20150 undefined-4.01 undefined-3.96 undefined
20140 undefined-1.97 undefined-2.24 undefined
20130 undefined-1.11 undefined-1.73 undefined
20120 undefined-0.55 undefined-0.67 undefined
20110 undefined-0.23 undefined-0.26 undefined

Ultragenyx Pharmaceutical business model

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that focuses on developing therapies for rare diseases. The company was founded in 2010 and is headquartered in Novato, California. The history of Ultragenyx began when the founder and CEO Emil Kakkis recognized the lack of medications for rare diseases. These diseases often affect a very small number of patients and there are few or no established treatment options. Ultragenyx decided to fill this gap and has been working since its inception to find new ways to develop therapies for rare diseases. The company's business model is based on utilizing innovative approaches to develop therapies for rare diseases and building close relationships with patient communities. Ultragenyx is divided into different divisions to address various disease areas. The largest division focuses on developing therapies for lysosomal storage diseases. These are a group of rare, inherited diseases caused by a deficiency of enzymes needed for the proper functioning of lysosomes in the body. Ultragenyx has developed several products in the field of lysosomal storage diseases, including an enzyme replacement therapy for the treatment of mucopolysaccharidosis VII, a rare metabolic disorder caused by a deficiency of the enzyme beta-glucuronidase. The company has also developed an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI. Another division of Ultragenyx focuses on developing therapies for genetically inherited metabolic disorders. These diseases are caused by mutations in genes that are responsible for important metabolic processes in the body. Ultragenyx has several drugs in the pipeline that focus on the treatment of genetically inherited metabolic disorders. Ultragenyx also has a division that focuses on the treatment of central nervous system (CNS) diseases. The company is working on therapies for various rare neurological disorders, including X-linked adrenoleukodystrophy and glycogen storage disease type II. Ultragenyx has developed flexible development platforms to quickly respond to the needs of patients with rare diseases. The company works closely with patient communities to receive feedback on medications and development plans. This helps the company to quickly address patient concerns and requirements and develop better therapies. Overall, Ultragenyx Pharmaceutical Inc. has a clear vision that is attributed to its business model and innovation culture. The company is committed to developing therapies for people with rare diseases that contribute to improving their quality of life. Ultragenyx has an impressive pipeline of drugs and is well positioned to continue to grow in the future and develop innovative therapies for rare diseases. Ultragenyx Pharmaceutical is one of the most popular companies on Eulerpool.com.

Ultragenyx Pharmaceutical Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ultragenyx Pharmaceutical Revenue by Segment

Segmente20222021202020192018
Collaboration and license222.71 M USD-219.32 M USD83.49 M USD-
Collaboration and License-256.44 M USD---
Product42.7 M USD----
Product Sales-21.4 M USD10.4 M USD4.3 M USD-
Non-cash Collaboration Royalty Revenue-17.95 M USD13 M USD--
Royalty21.69 M USD----
Collaboration and license----23.47 M USD
Product Sales----1.26 M USD
Collaboration and royalty236.72 M USD-143.09 M USD82.99 M USD-
Collaboration and Royalty-189.39 M USD---

Ultragenyx Pharmaceutical Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Ultragenyx Pharmaceutical Revenue by Segment

DateAll otherEuropeJapanLatin AmericaNorth AmericaUnited States of America
2022-36.37 M USD1.16 M USD44.71 M USD281.09 M USD-
202123.64 M USD26.66 M USD--301.11 M USD-
202012.05 M USD21.32 M USD--237.67 M USD-
20195.19 M USD12.09 M USD---86.44 M USD
2018863,000 USD5.29 M USD---45.34 M USD

Ultragenyx Pharmaceutical SWOT Analysis

Strengths

Ultragenyx Pharmaceutical Inc, a leading biopharmaceutical company, possesses several strengths that contribute to its success:

  • Strong portfolio of innovative and advanced therapies.
  • Robust research and development capabilities, leading to a pipeline of potential breakthrough treatments.
  • Well-established reputation and expertise in rare and ultra-rare genetic diseases.
  • Strategic partnerships with academic institutions, healthcare organizations, and industry leaders.
  • Solid financial position, enabling investments in growth and expansion.

Weaknesses

Despite its strengths, Ultragenyx Pharmaceutical Inc also faces certain weaknesses:

  • Reliance on a limited number of therapies, which may increase revenue vulnerability.
  • High research and development costs, impacting profitability.
  • Dependency on regulatory approvals, which can cause delays in product launches.
  • Limited market presence and market share compared to larger competitors.

Opportunities

Ultragenyx Pharmaceutical Inc can leverage the following opportunities to enhance its market position:

  • Growing global prevalence of rare genetic diseases, expanding the addressable market.
  • Advancements in genetic research and technology, providing opportunities for innovative treatments.
  • Potential collaborations and partnerships to access complementary expertise and resources.
  • Increasing demand for personalized medicine, aligning with the company's focus on genetic therapies.

Threats

Ultragenyx Pharmaceutical Inc should be mindful of the following threats that could impact its business:

  • Intense competition from both established pharmaceutical companies and emerging biotech firms.
  • Stringent regulatory requirements and potential delays or rejections in obtaining approvals.
  • Market uncertainties and economic fluctuations affecting healthcare spending.
  • Emergence of alternative treatment methods or breakthrough discoveries that could disrupt the market.

Ultragenyx Pharmaceutical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ultragenyx Pharmaceutical historical P/E ratio, EBIT multiple, and P/S ratio

Ultragenyx Pharmaceutical shares outstanding

The number of shares was Ultragenyx Pharmaceutical in 2023 — This indicates how many shares 73.544 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ultragenyx Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ultragenyx Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ultragenyx Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ultragenyx Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.73 -1.52  (12.01 %)2024 Q2
3/31/2024-1.77 -2.03  (-14.94 %)2024 Q1
12/31/2023-1.65 -1.52  (7.99 %)2023 Q4
9/30/2023-2.12 -2.23  (-5.2 %)2023 Q3
6/30/2023-2.12 -2.25  (-6.35 %)2023 Q2
3/31/2023-2.02 -2.33  (-15.58 %)2023 Q1
12/31/2022-2.18 -2.16  (1.14 %)2022 Q4
9/30/2022-1.85 -3.5  (-89.21 %)2022 Q3
6/30/2022-1.79 -2.26  (-26.47 %)2022 Q2
3/31/2022-1.8 -2.19  (-21.97 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Ultragenyx Pharmaceutical stock

Eulerpool World ESG Rating (EESG©)

70/ 100

🌱 Environment

46

👫 Social

99

🏛️ Governance

66

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees56.8
Percentage of women in management—
Percentage of Asian employees25.9
Share of Asian management23.2
Percentage of Hispanic/Latino employees8.6
Hispano/Latino Management share8.6
Percentage of Black employees6.5
Black Management Share4
Percentage of white employees55.5
White Management Share60.9
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ultragenyx Pharmaceutical shareholders

%
Name
Stocks
Change
Date
9.39372 % The Vanguard Group, Inc.8,658,1891,438,61112/31/2023
7.47216 % RTW Investments L.P.6,887,0861,481,99712/31/2023
4.79009 % Wellington Management Company, LLP4,415,029-780,85112/31/2023
4.46784 % Sands Capital Management, LLC4,118,0081,540,79112/31/2023
4.43252 % BlackRock Institutional Trust Company, N.A.4,085,450240,48612/31/2023
3.64076 % T. Rowe Price Associates, Inc.3,355,689280,04912/31/2023
3.52881 % State Street Global Advisors (US)3,252,502684,64412/31/2023
2.96064 % Kakkis (Emil D)2,728,82424,1433/1/2024
2.65433 % Federated Hermes Global Investment Management Corp.2,446,500250,00012/31/2023
2.58597 % ClearBridge Investments, LLC2,383,49289,92212/31/2023
1
2
3
4
5
...
10

Ultragenyx Pharmaceutical Executives and Management Board

Dr. Emil Kakkis62
Ultragenyx Pharmaceutical President, Chief Executive Officer, Director (since 2020)
Compensation 12.14 M
Mr. Dennis Huang58
Ultragenyx Pharmaceutical Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations
Compensation 4.24 M
Mr. Erik Harris53
Ultragenyx Pharmaceutical Executive Vice President, Chief Commercial Officer
Compensation 3.75 M
Mr. John Pinion57
Ultragenyx Pharmaceutical Chief Quality Officer, Executive Vice President - Translational Sciences
Compensation 3.71 M
Mr. Thomas Kassberg62
Ultragenyx Pharmaceutical Chief Business Officer, Executive Vice President (since 2016)
Compensation 2.46 M
1
2
3

Ultragenyx Pharmaceutical Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
REGENXBIO Stock
REGENXBIO
SupplierCustomer0,870,980,900,890,830,80
Bayer Stock
Bayer
SupplierCustomer0,690,85-0,10-0,45-0,51-0,28
Royalty Pharma A Stock
Royalty Pharma A
SupplierCustomer0,450,790,480,17-0,010,67
Solid Biosciences Stock
Solid Biosciences
SupplierCustomer0,330,490,640,750,850,88
Arcturus Therapeutics Stock
Arcturus Therapeutics
SupplierCustomer0,020,800,800,810,790,75
Kyowa Kirin Stock
Kyowa Kirin
SupplierCustomer-0,04-0,250,390,600,72-0,11
Daiichi Sankyo Stock
Daiichi Sankyo
SupplierCustomer-0,10-0,73-0,52-0,28-0,390,55
Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals
SupplierCustomer-0,390,110,670,17-0,23-0,74
Mereo BioPha Sp ADS Stock
Mereo BioPha Sp ADS
SupplierCustomer-0,550,770,460,640,840,66
Cambridge Cognition Hldgs Stock
Cambridge Cognition Hldgs
SupplierCustomer-0,830,690,450,130,42-0,39
1

Most common questions regarding Ultragenyx Pharmaceutical

What values and corporate philosophy does Ultragenyx Pharmaceutical represent?

Ultragenyx Pharmaceutical Inc represents values of innovation, commitment, and compassion in the field of biopharmaceuticals. The company strives to develop transformative therapies for rare and ultra-rare diseases, aiming to improve the lives of patients with limited treatment options. With a focus on rare genetic diseases, Ultragenyx is dedicated to advancing research and delivering breakthrough therapies that address unmet medical needs. By investing in cutting-edge science and leveraging strategic partnerships, Ultragenyx aims to make a positive impact in the lives of patients and their families.

In which countries and regions is Ultragenyx Pharmaceutical primarily present?

Ultragenyx Pharmaceutical Inc is primarily present in the United States.

What significant milestones has the company Ultragenyx Pharmaceutical achieved?

Some significant milestones achieved by Ultragenyx Pharmaceutical Inc include the approval of their first therapy, Mepsevii, by the U.S. FDA for the treatment of Mucopolysaccharidosis VII, a rare genetic disorder. They also successfully launched Crysvita, a treatment for X-linked hypophosphatemia, in the United States and Europe. Ultragenyx Pharmaceutical Inc has expanded its pipeline with multiple ongoing clinical trials for potential therapies aimed at rare diseases, including DTX401 for the treatment of Ornithine Transcarbamylase Deficiency. With a dedication to developing innovative therapies, Ultragenyx Pharmaceutical Inc continues to make advancements in the field of rare diseases.

What is the history and background of the company Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical Inc., headquartered in Novato, California, is a biopharmaceutical company focused on the development and commercialization of innovative treatments for rare genetic diseases. Founded in 2010, Ultragenyx has quickly established itself as a leader in the field of rare diseases, with a mission to bring hope to patients and their families. The company's extensive research and development efforts have resulted in the creation of a robust pipeline of potential therapies targeting different indications. Ultragenyx has also fostered collaborations with academic institutions and industry partners to further enhance its capabilities in discovering breakthrough treatments. With a strong commitment to improving patients' lives, Ultragenyx continues to drive innovation in the field of rare diseases.

Who are the main competitors of Ultragenyx Pharmaceutical in the market?

Ultragenyx Pharmaceutical Inc faces competition in the market from several other pharmaceutical companies. Some of its main competitors include BioMarin Pharmaceutical Inc, Regeneron Pharmaceuticals Inc, and Alexion Pharmaceuticals Inc. These companies operate in the same industry and develop similar innovative therapies and treatments. However, Ultragenyx Pharmaceutical Inc distinguishes itself through its focus on rare and ultra-rare diseases, providing unique solutions for patients in need.

In which industries is Ultragenyx Pharmaceutical primarily active?

Ultragenyx Pharmaceutical Inc is primarily active in the biotechnology industry.

What is the business model of Ultragenyx Pharmaceutical?

The business model of Ultragenyx Pharmaceutical Inc. revolves around developing and commercializing innovative treatments for rare and ultra-rare genetic diseases. Ultragenyx focuses on identifying these diseases with high unmet medical needs and strives to provide patients with effective therapies. The company aims to conduct extensive research and clinical trials to obtain regulatory approvals for its products. Ultragenyx also collaborates with external partners for research, development, and commercialization activities. By focusing on rare diseases, Ultragenyx aims to make a significant impact on the lives of patients and their families while delivering sustainable value to its stakeholders.

What is the P/E ratio of Ultragenyx Pharmaceutical 2024?

The Ultragenyx Pharmaceutical P/E ratio is -6.91.

What is the P/S ratio of Ultragenyx Pharmaceutical 2024?

The Ultragenyx Pharmaceutical P/S ratio is 7.47.

What is the AlleAktien quality score of Ultragenyx Pharmaceutical?

The AlleAktien quality score for Ultragenyx Pharmaceutical is 6/10.

What is the revenue of Ultragenyx Pharmaceutical 2024?

The expected Ultragenyx Pharmaceutical revenue is 547.23 M USD.

How high is the profit of Ultragenyx Pharmaceutical 2024?

The expected Ultragenyx Pharmaceutical profit is -591.17 M USD.

What is the business model of Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a US biotechnology company specializing in the development and commercialization of therapies for rare genetic diseases. The company is headquartered in Novato, California. Ultragenyx represents a part of the rapidly growing biotechnology industry driven by groundbreaking scientific advances and the demand for innovative treatment options. The company's core business includes research, development, and marketing of drugs for the treatment of rare genetic diseases. Ultragenyx focuses on diseases that have limited or no treatment options available. In this area, the company holds a leading position among biotech start-ups. The company's portfolio currently includes several products, including the enzyme replacement therapy classic Dojolvi, used for long-chain fatty acid oxidation disorders, and Crysvita, a medication for the treatment of a rare bone disease. Other products are still in clinical development. In recent years, Ultragenyx has also invested in gene therapies. The company is working on a novel gene therapy for the treatment of a rare, life-threatening metabolic disorder called GSD1a. A possible gene therapy could provide affected patients with lifelong and life-changing treatment. As a biotechnology company, Ultragenyx relies on partnerships and collaborations. The company has previously entered into strategic partnerships with other biotechnology and pharmaceutical companies to advance the development and commercialization of its products. The business model of Ultragenyx combines research, development, and marketing and aims to treat rare genetic diseases with limited or no current treatment options. Thanks to its focus on genetic diseases and gene therapies, as well as its partnerships, the company stands as one of the most promising biotech start-ups in the industry. In summary, the success model of Ultragenyx lies in identifying market gaps for the treatment of rare genetic diseases. Thanks to its developments in the field of enzyme replacement therapies and gene therapies, the company has established itself as a significant player in the biotechnology industry. The company pursues future opportunities through additional treatment options for rare genetic diseases, utilizing a business strategy based on partnerships and collaborations.

What is the Ultragenyx Pharmaceutical dividend?

Ultragenyx Pharmaceutical pays a dividend of 0 USD distributed over payouts per year.

How often does Ultragenyx Pharmaceutical pay dividends?

The dividend cannot currently be calculated for Ultragenyx Pharmaceutical or the company does not pay out a dividend.

What is the Ultragenyx Pharmaceutical ISIN?

The ISIN of Ultragenyx Pharmaceutical is US90400D1081.

What is the Ultragenyx Pharmaceutical WKN?

The WKN of Ultragenyx Pharmaceutical is A1XCY0.

What is the Ultragenyx Pharmaceutical ticker?

The ticker of Ultragenyx Pharmaceutical is RARE.

How much dividend does Ultragenyx Pharmaceutical pay?

Over the past 12 months, Ultragenyx Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ultragenyx Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Ultragenyx Pharmaceutical?

The current dividend yield of Ultragenyx Pharmaceutical is .

When does Ultragenyx Pharmaceutical pay dividends?

Ultragenyx Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Ultragenyx Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ultragenyx Pharmaceutical located?

Ultragenyx Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ultragenyx Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ultragenyx Pharmaceutical from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Ultragenyx Pharmaceutical pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Ultragenyx Pharmaceutical in the year 2023?

In the year 2023, Ultragenyx Pharmaceutical distributed 0 USD as dividends.

In which currency does Ultragenyx Pharmaceutical pay out the dividend?

The dividends of Ultragenyx Pharmaceutical are distributed in USD.

All fundamentals about Ultragenyx Pharmaceutical

Our stock analysis for Ultragenyx Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ultragenyx Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.